In vitro

ACI: NYC Bill to Restrict Safe Detergent Chemistry is Unnecessary, Would Disrupt Sustainable Innovation

Retrieved on: 
Thursday, February 8, 2024

(Photo: Businesswire)

Key Points: 
  • (Photo: Businesswire)
    “The innovation of water-soluble films and laundry detergent packets is a sustainability success story.
  • They help consumers safely use, dose and store the products, making chores easier to do for everyone, including those with disabilities.
  • They have grown in popularity because they provide a convenient way to deliver the correct dose of detergent for maximum cleaning efficiency, as well as enable more sustainable innovation.
  • ACI achieves this through a continuous commitment to sound science and being a credible voice for the cleaning products industry.

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Retrieved on: 
Tuesday, January 30, 2024

TEL AVIV, Israel, Jan. 30, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced publication of proteomic analyses that further demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The new studies reinforce the extensive existing evidence showing that Chemomab's first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes. The study, "The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data"1 has been published in the current online version of the peer-reviewed journal Cells.

Key Points: 
  • The new studies reinforce the extensive existing evidence showing that Chemomab's first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes.
  • The study, " The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data "1 has been published in the current online version of the peer-reviewed journal Cells.
  • CM-101 is a first-in-class CCL24-neutralizing monoclonal antibody whose dual anti-inflammatory and anti-fibrotic activity has demonstrated disease modifying potential in nonclinical studies of PSC and other fibro-inflammatory disorders.
  • CM-101 has Orphan Drug designation for PSC in the U.S. and the European Union and was recently awarded Fast Track designation by the FDA for the treatment of PSC in adults.

Dr. Ferrer BioPharma Named Finalist for CPhI Pharma Awards 2023

Retrieved on: 
Tuesday, October 24, 2023

Dr. Ferrer BioPharma (DFB) is honored to be a finalist for the prestigious CPhI Pharma Worldwide Awards 2023 , an internationally renowned award platform organized by CPhI, the world's leading pharmaceutical networking event.

Key Points: 
  • Dr. Ferrer BioPharma (DFB) is honored to be a finalist for the prestigious CPhI Pharma Worldwide Awards 2023 , an internationally renowned award platform organized by CPhI, the world's leading pharmaceutical networking event.
  • Dr. Gustavo Ferrer , founder of DFB, shared, "Being shortlisted by CPhI is a testament to our unwavering commitment to patient-focused innovation in addressing respiratory illnesses like COVID-19, influenza, post-COVID syndrome, and allergies."
  • The nozzle was carefully engineered to optimize nasal drug target delivery and maximize patient comfort.
  • The team also validated the specific angle of application for the treatment of viral illnesses and allergies.

Phillips-Medisize Teams with GlucoModicum to Develop an Innovative Needle-Free Continuous Glucose Monitor

Retrieved on: 
Tuesday, October 3, 2023

"We wanted to create a solution that is needle free, accurate and more affordable so people would better monitor their glucose," said Jokke Mäki, managing director of GlucoModicum.

Key Points: 
  • "We wanted to create a solution that is needle free, accurate and more affordable so people would better monitor their glucose," said Jokke Mäki, managing director of GlucoModicum.
  • "Working with Phillips-Medisize, we applied compelling science to develop a world-class product that may help billions of people better manage their diabetes."
  • While their scientists conducted rigorous research, GlucoModicum sought an experienced contract development and manufacturing organization (CDMO) to assist in realizing their vision for a new device, called Talisman.
  • Together, the companies are also beginning to explore other potential uses of this innovative technology to support management of other diseases.

Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

Retrieved on: 
Wednesday, May 31, 2023

Jonathan Douxfils, CEO at QUALIblood, said, "This contract represents a significant milestone for all parties, as it brings together the expertise of Q1 Scientific in providing world-class stability storage solutions with the renowned research capabilities of QUALIblood."

Key Points: 
  • Jonathan Douxfils, CEO at QUALIblood, said, "This contract represents a significant milestone for all parties, as it brings together the expertise of Q1 Scientific in providing world-class stability storage solutions with the renowned research capabilities of QUALIblood."
  • "We are excited to provide biological storage to QUALIblood, and its partners, to advance research, develop innovative solutions, and support the scientific community's efforts to improve healthcare outcomes," said Stephen Delaney, Managing Director at Q1 Scientific.
  • "This partnership fills a significant gap in the Belgium and broader European biobanking ecosystem, where there is a growing demand for secure and reliable storage solutions for biological samples."
  • Q1 Scientific's grand opening ceremony marked the formal inauguration of its new stability storage facility in Villers-le-Bouillet, which spans over 2,000 square meters and is equipped with cutting-edge temperature-controlled storage chambers and state-of-the-art monitoring and security systems.

Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

Retrieved on: 
Wednesday, May 31, 2023

Jonathan Douxfils, CEO at QUALIblood, said, "This contract represents a significant milestone for all parties, as it brings together the expertise of Q1 Scientific in providing world-class stability storage solutions with the renowned research capabilities of QUALIblood."

Key Points: 
  • Jonathan Douxfils, CEO at QUALIblood, said, "This contract represents a significant milestone for all parties, as it brings together the expertise of Q1 Scientific in providing world-class stability storage solutions with the renowned research capabilities of QUALIblood."
  • "We are excited to provide biological storage to QUALIblood, and its partners, to advance research, develop innovative solutions, and support the scientific community's efforts to improve healthcare outcomes," said Stephen Delaney, Managing Director at Q1 Scientific.
  • "This partnership fills a significant gap in the Belgium and broader European biobanking ecosystem, where there is a growing demand for secure and reliable storage solutions for biological samples."
  • Q1 Scientific's grand opening ceremony marked the formal inauguration of its new stability storage facility in Villers-le-Bouillet, which spans over 2,000 square meters and is equipped with cutting-edge temperature-controlled storage chambers and state-of-the-art monitoring and security systems.

Phillips-Medisize and U-Turn Audio Turn Up the Volume on Tonearm Performance for Next-Gen Turntables

Retrieved on: 
Tuesday, May 9, 2023

"The tonearm is basically the heart of the turntable," said Bob Hertig, president and CEO, U-Turn Audio.

Key Points: 
  • "The tonearm is basically the heart of the turntable," said Bob Hertig, president and CEO, U-Turn Audio.
  • The audiophiles and LP loyalists at U-Turn Audio realized that making its new tonearm from magnesium offered improved mechanical and physical properties over conventional materials.
  • To execute on its innovative tonearm concept, U-Turn Audio tapped the unique expertise of Phillips-Medisize, the largest magnesium injection molder in North America.
  • As a result, U-Turn Audio now is planning to ship the new tonearm on additional turntable models going forward.

Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis

Retrieved on: 
Wednesday, December 1, 2021

SAN DIEGO, CA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of pathogen-associated indications that precipitate sepsis, today announced that preclinical invitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma.

Key Points: 
  • The invitro clearance of both targets was rapid, with an ~50% reduction of PG at one hour and a ~70% reduction of LTA at two hours.
  • In addition to being potent activators of sepsis, there is a heightened interest in gram-positive pathogens based on the continuing emergence of drug resistant species, including antibiotic-resistant Staphylococcus aureus (MRSA).
  • Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated indications that precipitate sepsis, the #1 cause of hospital deaths worldwide.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines

Retrieved on: 
Wednesday, August 4, 2021

SOLANA BEACH, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced the publication of study results in Medical Cannabis and Cannabinoids, a peer-reviewed journal. The study and related article, entitled “The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines,” compared the in vitro effects of purified natural and synthetic forms of Cannabidiol (CBD) to establish any pharmacological differences in human cell lines. The study found no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD.

Key Points: 
  • The study and related article, entitled The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines , compared the in vitro effects of purified natural and synthetic forms of Cannabidiol (CBD) to establish any pharmacological differences in human cell lines.
  • The study found no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD.
  • The company-sponsored study was led by Prof. Saoirse OSullivan, scientific advisor to Artelo Biosciences and former Professor of Pharmacology at the University of Nottingham, UK.
  • Artelo Biosciences, Inc.is a clinical stage biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid signaling pathways, including the endocannabinoid system.

Worldwide In-vitro Transcription Templates Industry to 2030 - by Disease, Treatment, Research Stage, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021

The report also provides the compound annual growth rate (CAGR) for the global in-vitro transcription templates market during the forecast period.

Key Points: 
  • The report also provides the compound annual growth rate (CAGR) for the global in-vitro transcription templates market during the forecast period.
  • Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global in-vitro transcription templates market.
  • Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global in-vitro transcription templates market.
  • What will be the Y-o-Y growth of the global in-vitro transcription templates market between 2020 and 2030?